Aurobindo Pharma rises on disposal of its US subsidiary

Aurobindo Pharma rises on disposal of its US subsidiary

Chinmayee D
/ Categories: Trending, DSIJ News

Aurobindo Pharma Limited, a manufacturer of generic pharmaceuticals & active pharmaceutical ingredients (APIs) announced on Monday that it has signed an agreement to sell its US-based wholly-owned subsidiary, Natrol LLC to an affiliate of New Mountain Capital to combine with Jarrow Formulas. Reacting to the news, the share of Aurobindo Pharma gained nearly 4 per cent during the early trading session on Monday.

The all-cash transaction is priced at Rs 4,048 crore at the current exchange rate (USD 550 million). The transaction is expected to close by January 2021, subject to the customary closing conditions and regulatory approvals. Proceeds from the divestiture will be used for the reduction of debt and other new strategic initiatives.

Since the acquisition of the assets of Natrol in December 2014, the business has been consistently profitable and growing on all fronts under the ownership of Aurobindo Pharma.

The company is evaluating and concluding strategic options towards focussed portfolio enhancement with the ultimate objective of enhancing stakeholder values.

Aurobindo Pharma engages in formulation & APIs and caters to more than 100 countries. Location-wise, the company earns 50.5 per cent revenue from the USA, 31.7 per cent from Europe, 9.9 per cent from India, and 7.9 per cent from the rest of the world.

At 12.35 pm today, its share was trading 0.87 per cent higher at Rs 789.9. It recorded an intraday high of Rs 814.3 on BSE.

Previous Article Bearish Monday: Sensex tumbles 500 points, mid-caps bleed; here are 3 reasons why
Next Article Three categories of funds generating best SIP returns
Rate this article:
3.3

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR